David F. Penson, M.D., M.P.H., MMHC
- Co-Leader, Cancer Health Outcomes and Control Research Program
- Paul V. Hamilton, M.D. and Virginia E. Howd Professor of Urologic Oncology
- Professor and Chair, Department of Urology
- Professor of Medicine
- Professor of Health Policy
- Director, Center for Surgical Quality and Outcomes Research
Phone
Vanderbilt University Medical Center
2525 West End Avenue, Suite 1200
Nashville, TN 37203-1738
2525 West End Avenue, Suite 1200
Nashville, TN 37203-1738
David F. Penson, M.D., M.P.H., MMHC
- Co-Leader, Cancer Health Outcomes and Control Research Program
- Paul V. Hamilton, M.D. and Virginia E. Howd Professor of Urologic Oncology
- Professor and Chair, Department of Urology
- Professor of Medicine
- Professor of Health Policy
- Director, Center for Surgical Quality and Outcomes Research
615-343-1529
david.penson@vumc.org
Vanderbilt University Medical Center
2525 West End Avenue, Suite 1200
Nashville, TN 37203-1738
2525 West End Avenue, Suite 1200
Nashville, TN 37203-1738
Research Program
Departments/Affiliations
Provider Information
Profile
Dr. Penson is a board-certified urologic oncologist who focuses on urological malignancies, particularly bladder and prostate cancer. He is an internationally recognized expert in the care of both of these common cancers and is also a federally funded researcher with a focus on patient-reported outcomes, survivorship and comparative effectiveness in prostate cancer. He serves as the American Urologic Association National Chair for Healthcare Policy and is the organization's representative to the Commission on Cancer.
Education
- M.Mgt., Vanderbilt University, Nashville, Tennessee (2014)
- M.P.H., Yale University School of Medicine, New Haven, Connecticut (2001)
- M.D., Boston University, Boston, Massachusetts (1991)
- B.A., University of Pennsylvania, Bloomsburg, Pennsylvania (1987)
Postgraduate Training
- General Surgery Internship -UCLA Health System, 1992
- General Surgery Residency - UCLA Health System, 1993
- Urology Residency - UCLA Health System, 1997
- Fellowship - Yale University School of Medicine, 1999
Research Emphasis
Research Description
Publications
- Tyson MD, Alvarez J, Koyama T, Hoffman KE, Resnick MJ, Wu XC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Paddock LE, Stroup A, Chen VW, Penson DF, Barocas DA. Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study. Eur. Urol [print-electronic]. 2017 Aug; 72(2): 307-14. PMID: 27816300, PMCID: PMC5413424, PII: S0302-2838(16)30750-3, DOI: 10.1016/j.eururo.2016.10.036, ISSN: 1873-7560.
- Penson DF. Quality of Life Outcomes Following Treatment for Localized Prostate Cancer: What's New and What's Not [editorial]. Eur. Urol [print-electronic]. 2017 Jul 7/20/2017; PMID: 28735902, PII: S0302-2838(17)30588-2, DOI: 10.1016/j.eururo.2017.07.010, ISSN: 1873-7560.
- Hoffman RM, Lo M, Clark JA, Albertsen PC, Barry MJ, Goodman M, Penson DF, Stanford JL, Stroup AM, Hamilton AS. Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study. J. Clin. Oncol [print-electronic]. 2017 Jul 7/10/2017; 35(20): 2306-14. PMID: 28493812, PMCID: PMC5501361, DOI: 10.1200/JCO.2016.70.6317, ISSN: 1527-7755.
- Ark JT, Alvarez JR, Koyama T, Bassett JC, Blot WJ, Mumma MT, Resnick MJ, You C, Penson DF, Barocas DA. Variation in the Diagnostic Evaluation among Persons with Hematuria: Influence of Gender, Race and Risk Factors for Bladder Cancer. J. Urol [print-electronic]. 2017 Jun 6/24/2017; PMID: 28655530, PII: S0022-5347(17)76746-8, DOI: 10.1016/j.juro.2017.06.083, ISSN: 1527-3792.
- Hoffman RM, Van Den Eeden SK, Davis KM, Lobo T, Luta G, Shan J, Aaronson D, Penson DF, Leimpeter AD, Taylor KL. Decision-making processes among men with low-risk prostate cancer: A survey study. Psychooncology [print-electronic]. 2017 Jun 6/13/2017; PMID: 28612468, DOI: 10.1002/pon.4469, ISSN: 1099-1611.
- Noud M, Hovis K, Gelbard A, Sathe NA, Penson DF, Feurer ID, McPheeters ML, Francis DO. Patient-Reported Outcome Measures in Upper Airway-Related Dyspnea: A Systematic Review. JAMA Otolaryngol Head Neck Surg [print-electronic]. 2017 Jun 6/8/2017; PMID: 28594976, PII: 2630822, DOI: 10.1001/jamaoto.2017.0348, ISSN: 2168-619X.
- Sundaram KM, Chang SS, Penson DF, Arora S. Therapeutic Ultrasound and Prostate Cancer. Semin Intervent Radiol [print-electronic]. 2017 Jun; 34(2): 187-200. PMID: 28579687, PMCID: PMC5453783, PII: 001008, DOI: 10.1055/s-0037-1602710, ISSN: 0739-9529.
- Lee DJ, Mallin K, Graves AJ, Chang SS, Penson DF, Resnick MJ, Barocas DA. Recent changes in prostate cancer screening practices and prostate cancer epidemiology. J. Urol [print-electronic]. 2017 May 5/25/2017; PMID: 28552708, PII: S0022-5347(17)74517-X, DOI: 10.1016/j.juro.2017.05.074, ISSN: 1527-3792.
- Patel DA, Sharda R, Hovis KL, Nichols EE, Sathe N, Penson DF, Feurer ID, McPheeters ML, Vaezi MF, Francis DO. Patient-reported outcome measures in dysphagia: a systematic review of instrument development and validation. Dis. Esophagus. 2017 May 5/1/2017; 30(5): 1-23. PMID: 28375450, PII: 3092445, DOI: 10.1093/dote/dow028, ISSN: 1442-2050.
- Glaser ZA, Love HD, Guo S, Gellert L, Chang SS, Herrell SD, Barocas DA, Penson DF, Cookson MS, Clark PE. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma. Urol. Oncol [print-electronic]. 2017 May; 35(5): 286-93. PMID: 28108243, PII: S1078-1439(16)30420-3, DOI: 10.1016/j.urolonc.2016.12.012, ISSN: 1873-2496.
- Lang MF, Tyson MD, Alvarez JR, Koyama T, Hoffman KE, Resnick MJ, Cooperberg MR, Wu XC, Chen V, Paddock LE, Hamilton AS, Hashibe M, Goodman M, Greenfield S, Kaplan SH, Stroup A, Penson DF, Barocas DA. The Influence of Psychosocial Constructs on the Adherence to Active Surveillance for Localized Prostate Cancer in a Prospective, Population-based Cohort. Urology [print-electronic]. 2017 May; 103: 173-8. PMID: 28189554, PMCID: PMC5410889, PII: S0090-4295(17)30123-1, DOI: 10.1016/j.urology.2016.12.063, ISSN: 1527-9995.
- Tsai HT, Pfeiffer RM, Philips GK, Barac A, Fu AZ, Penson DF, Zhou Y, Potosky AL. Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study. J. Urol [print-electronic]. 2017 May; 197(5): 1251-7. PMID: 27993663, PII: S0022-5347(16)31954-1, DOI: 10.1016/j.juro.2016.12.022, ISSN: 1527-3792.
